deltatrials
Completed PHASE1 NCT00003385

Combination Chemotherapy in Treating Patients With Untreated Ovarian, Peritoneal, or Fallopian Tube Cancer

A Phase I Study of Paclitaxel, Carboplatin, and Increasing Doses of Doxil in Untreated Ovarian, Peritoneal, and Tubal Carcinoma

Sponsor: Gynecologic Oncology Group

Conditions Fallopian Tube Cancer Ovarian Cancer Primary Peritoneal Cavity Cancer
Interventions carboplatin paclitaxel pegylated liposomal doxorubicin hydrochloride
Updated 6 times since 2017 Last updated: May 24, 2013 Started: Mar 31, 1999 Primary completion: Jan 31, 2007

A PHASE1 clinical study on Fallopian Tube Cancer and Ovarian Cancer, this trial is completed. The trial is conducted by Gynecologic Oncology Group and has accumulated 6 data snapshots since 1999. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Feb 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Feb 2021 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Mar 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Gynecologic Oncology Group
  • National Cancer Institute (NCI)
Data source: GOG Foundation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bethesda, United States
  • • Cleveland, United States
  • • Galveston, United States
  • • Honolulu, United States
  • • Iowa City, United States
  • • Oslo, Norway
  • • Seattle, United States